Accelerating Patient Enrollment in Global Clinical Trials
- Patient Screening — Partnering with Predicine to screen samples sent from the clinical trials sites to identify those containing the target alterations for enrollment. With the increased sensitivity and comprehensive detection range patients that failed tissue testing may actually be eligible for enrollment.
- Patient Referral — Predicine will work with you to match and refer patients from our screened pool, to enable access to a new channel, especially for China patient, reduce the screening effort, and increase enrollment rate.
- Patient Stratification — Monitor patient tumor burden and genetic alterations over time, distinguishing responders and non-responders.
- Novel Target Discovery — Access to Predicine’s well annotated database from private and publicly collected data, for novel target discovery and validation.
- Co-development CDx — Co-develop companion diagnostics using Predicine’s proprietary technology and customized panel. Predicine will work with FDA and CFDA (Chinese FDA) to support Companion Diagnostic regulatory affairs.